Companies: 48,874 Total Market Cap: 132460447025120.92

Daiichi Sankyo Company, Limited

TYO-4568
Healthcare Drug Manufacturers - General
Rank #455
Market Cap 47.77 B
Volume 8.56 M
Price 25.51
Change (%) 7.06%
Country or region Japan Japan

Daiichi Sankyo Company, Limited's latest marketcap:

47.77 B

As of 05/19/2025, Daiichi Sankyo Company, Limited's market capitalization has reached $47.77 B. According to our data, Daiichi Sankyo Company, Limited is the 455th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 47.77 B
Revenue (ttm) 13.01 B
Net Income (ttm) 2.04 B
Shares Out 1.87 B
EPS (ttm) 1.08
Forward PE 23.36
Ex-Dividend Date 03/28/2025
Earnings Date 04/25/2025
Market Cap Chart
Data Updated: 05/19/2025

Daiichi Sankyo Company, Limited's yearly market capitalization.

Daiichi Sankyo Company, Limited has seen its market value grow from ¥6.86 T to ¥6.93 T since 2020, representing a total increase of 1.02% and an annual compound growth rate (CAGR) of 0.23%.
Date Market Cap Change (%)
05/19/2025 ¥6.93 T -19.23%
12/30/2024 ¥8.20 T 10.41%
12/29/2023 ¥7.42 T -8.87%
12/30/2022 ¥8.15 T 45.32%
12/30/2021 ¥5.61 T -18.22%
12/30/2020 ¥6.86 T

Company Profile

About Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited is a global pharmaceutical company headquartered in Tokyo, Japan. Founded in 1899, the company specializes in manufacturing and selling pharmaceutical products across Japan, North America, Europe, and other international markets.

Key Products and Treatments

  • Oncology: Enhertu (HER2-positive cancers), Turalio (CSF1R/KIT/FLT3-ITD mutations), Vanflyta (acute myeloid leukemia).
  • Cardiovascular & Metabolic: Liziana, Savaysa (direct factor Xa inhibitors), Minnebro, Olmetec (antihypertensives), Nilemdo (cholesterol-lowering), Nustendi (bempedoic acid/ezetimibe).
  • Neurology & Pain Management: Emgalty, Reyvow (migraine), Vimpat (anti-seizure), Tarlige (neuropathic pain).
  • Hematology & Bone Health: Injectafer (iron deficiency), Pralia (osteoporosis), Ranmark (bone metastasis complications).
  • Vaccines: COVID-19, influenza, measles/rubella, mumps, and H5N1 vaccines.

Strategic Collaborations

The company partners with Merck & Co., Inc. and AstraZeneca UK Limited to develop innovative anti-cancer drugs, enhancing its global oncology portfolio.

With over a century of expertise, Daiichi Sankyo continues to advance healthcare through cutting-edge research and patient-focused solutions.

Frequently Asked Questions

As of 05/19/2025, Daiichi Sankyo Company, Limited (including the parent company, if applicable) has an estimated market capitalization of $47.77 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.

Daiichi Sankyo Company, Limited global market capitalization ranking is approximately 455 as of 05/19/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

Stock Detail

Country or region Japan
Founded 1899
IPO Date n/a
Employees 18,726
CEO Hiroyuki Okuzawa
Sector Healthcare
Industry Drug Manufacturers - General
Address 3-5-1, Nihonbashi-honcho
Tokyo, 103-8426
Japan
Website https://www.daiichisankyo.com
People Also Watch
Eli Lilly
755.11 7.06%
JNJ
152.49 7.06%
AbbVie
185.71 7.06%
Novo Nordisk
67.02 7.06%